Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Life extension

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,127 result(s) found for: Life extension. Displaying page 1 of 57.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2017-000748-16 Sponsor Protocol Number: MT-2-01 Start Date*: 2017-09-14
    Sponsor Name:Minoryx Therapeutics S.L.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTINATIONAL, MULTICENTER STUDY WITH OPEN-LABEL TREATMENT EXTENSION TO ASSESS THE EFFECT OF MIN-102 ON THE PROGRESSION OF ADRENOMYELONEUROPATHY IN M...
    Medical condition: ADRENOMYELONEUROPATHY IN MALE PATIENTS WITH X-LINKED ADRENOLEUKODYSTROPHY
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) HU (Completed) ES (Ongoing) NL (Completed) PL (Prematurely Ended) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000389-69 Sponsor Protocol Number: UX007G-CL202 Start Date*: 2017-01-27
    Sponsor Name:Ultragenyx Pharmaceutical Inc
    Full Title: An Open-label Extension Study to Assess the Long-term Safety and Efficacy of UX007 in Subjects with Glucose Transporter Type 1 Deficiency Syndrome
    Medical condition: Glucose Transporter Type 1 deficiency syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10061032 Carbohydrate transport disorder LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003817-16 Sponsor Protocol Number: KIN001-202 Start Date*: 2019-04-04
    Sponsor Name:Kinarus AG
    Full Title: A 52 weeks double blind, randomized and placebo controlled trial evaluating the effect of oral KIN001 150 mg plus pioglitazone 10 mg daily on injection frequency of Standard of Care in patients wit...
    Medical condition: wet age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10075568 Wet age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-001243-36 Sponsor Protocol Number: BIA-2093-311/EXT Start Date*: 2015-11-06
    Sponsor Name:BIAL - Portela & Ca, S.A.
    Full Title: EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2-093) AS MONOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED PARTIAL-ONSET SEIZURES: A DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, MU...
    Medical condition: Adult patients with recently diagnosed partial-onset seizures
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004852 10065336 Partial epilepsy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) HU (Completed) LT (Completed) CZ (Completed) LV (Completed) PT (Completed) BE (Completed) FR (Completed) ES (Completed) SE (Completed) EE (Completed) AT (Completed) BG (Completed) SK (Completed) FI (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003321-42 Sponsor Protocol Number: NL58948.091.16 Start Date*: 2017-01-18
    Sponsor Name:Radboud University Medical Centre
    Full Title: Lengthening Adalimumab Dosing Interval in quiescent Crohn’s disease patients: the LADI study.
    Medical condition: Crohn's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-005184-13 Sponsor Protocol Number: 50129 Start Date*: 2017-11-29
    Sponsor Name:MEDIOLANUM FARMACEUTICI S.P.A.
    Full Title: METRO STUDY - MESOGLYCAN VERSUS PLACEBO IN SECONDARY PREVENTION OF SURFACE VEIN THROMBOSIS
    Medical condition: patients with SVT of the lower limbs that have completed the acute phase treatment cycle
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001265-28 Sponsor Protocol Number: ISD003-P144-08 Start Date*: 2008-06-17
    Sponsor Name:ISDIN
    Full Title: “Estudio abierto de extensión con P144 para la ampliación del tratamiento tópico de la fibrosis cutánea de pacientes con esclerosis sistémica previamente tratados en el ensayo ISD002-P144-07" “Op...
    Medical condition: "Fibrosis cutánea de pacientes con esclerosis sistémica" "Skin fibrosis in patients with systemic sclerosis"
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039710 Scleroderma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Completed) HU (Prematurely Ended) GB (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002739-17 Sponsor Protocol Number: AN-EPI3331 Start Date*: 2015-12-30
    Sponsor Name:ANTHERA Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Open-Label, Assessor-Blind, Non-Inferiority, Active Comparator Study Evaluating the Efficacy and Safety of Liprotamase in Subjects with Cystic Fibrosis-Related Exocrine Pancr...
    Medical condition: Pancreatic exocrine Insufficiency due to Cystic Fibrosis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004331-71 Sponsor Protocol Number: IB1001-201 Start Date*: 2019-05-08
    Sponsor Name:IntraBio Ltd
    Full Title: Effects of N-Acetyl-L-Leucine on Niemann-Pick type C Disease (NPC): A multinational, multi-center, open-label, rater-blinded Phase II study
    Medical condition: Niemann-Pick Disease type C (NPC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10010331 Congenital, familial and genetic disorders SOC
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) SK (Completed)
    Trial results: View results
    EudraCT Number: 2019-001792-37 Sponsor Protocol Number: CQGE031C2302E1 Start Date*: 2020-04-22
    Sponsor Name:Novartis Pharma AG
    Full Title: A multi-center, double-blinded and open-label extension study to evaluate the efficacy and safety of ligelizumab as retreatment, self-administered therapy and monotherapy in Chronic Spontaneous Urt...
    Medical condition: Chronic Spontaneous Urticaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10072757 Chronic spontaneous urticaria PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) FR (Prematurely Ended) CZ (Completed) ES (Prematurely Ended) DE (Prematurely Ended) AT (Completed) GR (Prematurely Ended) EE (Completed) IT (Prematurely Ended) BE (Completed) SK (Prematurely Ended) DK (Prematurely Ended) PL (Prematurely Ended) NL (Temporarily Halted) BG (Prematurely Ended) HR (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2019-002566-13 Sponsor Protocol Number: NEXT-MS Start Date*: 2019-12-19
    Sponsor Name:Amsterdam University Medical Center
    Full Title: Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis
    Medical condition: Relapsing remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004852 10070425 Multiple sclerosis exacerbation LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-000985-39 Sponsor Protocol Number: CAIN457A2304E1 Start Date*: 2012-09-17
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, double-blind and open label, 4 year extension study of subcutaneous secukinumab in prefilled syringes, assessing long-term safety, tolerability and efficacy in subjects with moderate...
    Medical condition: Moderate to severe chronic plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) SK (Completed) DE (Completed) AT (Completed) IT (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-003788-28 Sponsor Protocol Number: PR3079 Start Date*: 2007-11-05
    Sponsor Name:Pantarhei Bioscience B.V.
    Full Title: A double-blind, placebo controlled, randomized, comparative, mono-centre trial to assess the effects on the androgen metabolism and its effects on biochemical parameters, mood, fat, muscle and bone...
    Medical condition: Biochemical disturbances (androgens, lipids, bone markers, endocrine) and mood disturbances caused by the use of Oral Contraception (OC).
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-004406-25 Sponsor Protocol Number: IB1001-202 Start Date*: 2019-05-09
    Sponsor Name:IntraBio Ltd
    Full Title: Effects of N-Acetyl-L-Leucine on GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease): A multinational, multicenter, open-label, rater-blinded Phase II study.
    Medical condition: GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10010331 Congenital, familial and genetic disorders SOC
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2009-015768-33 Sponsor Protocol Number: EMR700773-003/BMN162-503 Start Date*: 2011-01-04
    Sponsor Name:BioMarin International Ltd.
    Full Title: A Phase IIIb, Multicentre, Open-Label, Randomized, Controlled Study of the Efficacy, Safety, and Population Pharmacokinetics of Sapropterin Dihydrochloride (Kuvan®) in Phenylketonuria (PKU) Patient...
    Medical condition: Phenylketonuria
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004850 10034873 Phenylketonuria (PKU) LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) SK (Completed) DE (Completed) AT (Completed) CZ (Completed) PT (Completed) BE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-002460-29 Sponsor Protocol Number: EASIC30505 Start Date*: 2005-09-12
    Sponsor Name:Rheumazentrum Ruhrgebiet.
    Full Title: An Open Extension, Investigator Initiated Trial, to Examine Radiographic Progression, Efficacy and Safety, of Long-Term Treatment with Infliximab in Patients with Ankylosing Spondylitis EASIC...
    Medical condition: Ankylosing spondylitis (AS)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) FI (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004311-31 Sponsor Protocol Number: 0177/DEV Start Date*: 2013-03-20
    Sponsor Name:Develco Pharma Schweiz AG
    Full Title: Randomised, double-blind, placebo-controlled, parallel-group design, multi-centre, dose-escalation phase III trial to investigate the efficacy, safety, and tolerability of Naloxone HCl PR tablets a...
    Medical condition: Opioid-induced bowel dysfunction (OBD) involves not only constipation, but also a constellation of symptoms including incomplete evacuation, bloating, abdominal distension, and increased gastric re...
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004856 10071128 Opioid induced constipation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed) CZ (Completed) DE (Completed) GB (Completed) SK (Completed) ES (Completed) IT (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003218-14 Sponsor Protocol Number: 0176/DEV Start Date*: 2013-01-22
    Sponsor Name:Develco Pharma Schweiz AG
    Full Title: Randomised, double-blind, placebo-controlled, parallel-group design, multi-centre, dose-escalation phase III trial to investigate the efficacy, safety, and tolerability of Naloxone HCl PR tablets a...
    Medical condition: Opioid-induced bowel dysfunction (OBD) involves not only constipation, but also a constellation of symptoms including incomplete evacuation, bloating, abdominal distension, and increased gastric re...
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004856 10071128 Opioid induced constipation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) CZ (Completed) SK (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004066-10 Sponsor Protocol Number: MVT-601-3103 Start Date*: 2018-10-19
    Sponsor Name:Myovant Sciences GmbH
    Full Title: SPIRIT EXTENSION: An International Phase 3 Open-Label, Single-Arm, Safety and Efficacy Extension Study to Evaluate Relugolix Co-Administered with Low-Dose Estradiol and Norethindrone Acetate in Wom...
    Medical condition: Endometriosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038604 - Reproductive system and breast disorders 10014778 Endometriosis PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) HU (Completed) BE (Completed) FI (Completed) SE (Completed) PL (Completed) CZ (Completed) BG (Completed) PT (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-001225-41 Sponsor Protocol Number: M14-430 Start Date*: 2018-04-17
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo- Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Comp...
    Medical condition: Crohn's Disease (CD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Trial now transitioned) DK (Trial now transitioned) AT (Trial now transitioned) DE (Trial now transitioned) SE (Trial now transitioned) LV (Trial now transitioned) GB (GB - no longer in EU/EEA) PT (Trial now transitioned) FR (Trial now transitioned) HU (Trial now transitioned) NL (Trial now transitioned) IE (Completed) LT (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) BG (Completed) BE (Trial now transitioned) SI (Completed) HR (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 12:50:36 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA